Study of Reducing or Stopping Antipsychotic Medicines in Adults with Psychotic Disorders

What this Trial Is About

The trial investigates deprescribing antipsychotic medications in adults with psychotic or related disorders who are on long-term treatment and clinically stable. It aims to better understand the challenges and successes of reducing or stopping antipsychotics in real-life settings, addressing the concerns about relapse and side effects. This observational study seeks to provide practical insights for clinicians and patients about deprescribing strategies. Participants in this study are patients who accept or request deprescription of their antipsychotic medication between January 1, 2021, and October 30, 2025. The study will observe clinical situations where discontinuation or reduction of antipsychotics below the minimum recommended doses is possible. The study does not involve specific treatment interventions but follows patients over time as they undergo deprescribing. During up to 12 months of follow-up, researchers will describe and analyze clinical cases of antipsychotic dose reduction or discontinuation. The study will collect data on the patients clinical status, treatment changes, and outcomes related to deprescribing. This will help identify which situations allow safe reduction and how patients respond, contributing to improved guidance for managing antipsychotic treatments.

Deprescribing Antipsychotics: a Multiple Case Study